Chelidonium majus

Within the SIRIAM Platform, Chelidonium majus is classified as a Regional Signature Component.

Unlike the universal Structural & Dermal Support Core, Release Core and Integration Core ingredients, Chelidonium majus is incorporated selectively into specific regional formulations according to their intended neurodermal objectives.

Within the SIRIAM formulation philosophy, Regional Signature Components provide anatomical specificity to individual formulations. Chelidonium majus therefore contributes to the physiological identity of selected preparations without altering the common pharmaceutical architecture shared across the platform.

Its incorporation reflects the SIRIAM principle of combining established pharmaceutical science with carefully selected botanical ingredients that possess biologically plausible mechanisms while acknowledging the absence of direct evidence for region-specific neurodermal application.

Chelidonium majus (Greater Celandine) is a perennial medicinal plant belonging to the Papaveraceae family and has been used in traditional European herbal medicine for centuries.

The plant contains a diverse range of biologically active constituents, including:

Isoquinoline alkaloids (chelidonine, chelerythrine, sanguinarine, berberine and coptisine);

flavonoids;

phenolic acids;

carotenoids;

organic acids.

Experimental investigations have demonstrated several biological mechanisms, including:

modulation of inflammatory signalling pathways;

antioxidant activity;

antimicrobial effects;

influence on epithelial cell proliferation;

modulation of apoptosis in laboratory models;

effects on smooth muscle physiology;

experimental neuroprotective and cytoprotective properties.

Historically, Chelidonium majus has been associated with hepatobiliary disorders in traditional herbal medicine. Modern clinical evidence for these indications remains limited and inconsistent, and concerns regarding rare idiosyncratic hepatotoxicity following oral administration have resulted in increased regulatory scrutiny in several countries.

Topically, Chelidonium majus has primarily been investigated for dermatological applications such as viral warts, where the plant's latex has demonstrated antiviral and keratolytic properties in limited clinical and observational studies. However, robust controlled clinical evidence remains limited.

Experimental dermatological studies suggest biological activity relevant to epithelial physiology, but high-quality clinical evidence for broader topical indications is lacking.

Current scientific evidence evaluates Chelidonium majus as an isolated botanical extract or within conventional herbal preparations.

No published studies currently investigate Chelidonium majus within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform. Consequently, its inclusion reflects biological plausibility together with the architectural philosophy of the platform rather than established evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Chelidonium majus functions as a Regional Signature Component.

Its architectural purpose is to contribute to the biological identity of selected regional formulations while remaining independent of the universal platform architecture.

Future optimisation may refine extract standardisation and concentration according to pharmaceutical validation.